Web News Insider
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
Failure to meet the 62‑day target could leave thousands of bladder‑cancer patients waiting longer for surgery, raising survival risks.
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
The new perioperative regimen cuts death risk by 42% in cisplatin-ineligible patients, marking a major expansion for AstraZeneca’s oncology portfolio.
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
The IRS raised the health Flexible Spending Account cap to $3,500 starting in 2027, giving employees a chance to lower taxable income…
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
Fidelity’s new retirement investing strategy impacts fees and access for average 401(k) savers, requiring careful review of statements.
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
Break down the concept of RMDs, their rules, current age thresholds, and practical tips like Roth conversions for managing tax implications.
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
Exploring how Kazia Therapeutics’ novel nuclear PD-L1 protein degrader, NDL2, works to overcome immunotherapy resistance in advanced solid tumors.
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
Discover the preliminary clinical evidence thresholds cell therapies must achieve to secure simultaneous FDA RMAT and Fast Track designations.
-
How Retirement Savers Can Close the Gap Left by the Fading Three-Legged Stool
Discover actionable strategies to diversify income sources and boost personal savings rates as the traditional retirement model collapses.
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
The IRS raises the elective deferral limit by $1,000 and expands catch-up contributions for workers 50 and older, creating new tax-deferral opportunities.
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
Following successful Phase 3 trial results, mRNA platforms are emerging as a versatile, rapid tool for training the immune system to target…
-
IRS Raises Annual Gift Exclusion to $20,000 for 2027, Enabling $320,000 Tax-Free Transfer for Couples
Inflation adjustment allows married couples to gift $40,000 per recipient annually without filing returns, accelerating estate reduction for high-net-worth families.
-
NHS rolls out first targeted anal cancer drug, extending survival to nearly three years
Retifanlimab plus chemotherapy adds 10 months of life for 250 patients annually in England, available immediately.
-
Divorcing One Month Early Can Cost $700 Monthly in Social Security for Life
The 10-year marriage rule for divorced spousal and survivor benefits creates a permanent financial cliff that many near the threshold overlook.
-
Medicare Part D Cap Rise to $2,400 Outweighs 2027 Ozempic Price Cuts
Patients relying on maintenance drugs like Ozempic face higher annual spending caps in 2027 despite new Medicare price negotiations.
-
How the OncoMate MSI Dx Test Guides Pembrolizumab Therapy
Discover how the OncoMate MSI Dx test uses PCR technology to identify MSI-H solid tumors and match patients with pembrolizumab immunotherapy.
-
Financial and Systemic Barriers Impede Early Bladder Cancer Care for Younger Veterans
A new national survey reveals that 63% of military service members and veterans with non-muscle invasive bladder cancer face severe systemic care…
-
Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial
A new study shows that adding an experimental drug to standard chemotherapy significantly improves survival outcomes for patients with metastatic pancreatic cancer.
-
Why Achieve Says Most Americans Feel Their Financial Stability is Slipping Away
A new survey reveals that 71% of U.S. consumers feel their finances are stagnating, highlighting the growing reliance on debt to cover…
-
Locking In High Yields: How Current CD Rates Offer Safe Returns Amid Shifting Economic Outlooks
As the Federal Reserve shifts course on interest rates, high-yield certificates of deposit offer savers guaranteed returns up to 5.05% APY.
-
Factor XIa Inhibitor Asundexian Cuts Recurrent Stroke Risk Without Raising Major Bleeding
FDA approval of Bayer’s asundexian shows a 26% drop in ischemic strokes while keeping major‑bleed rates comparable to placebo, offering a safer…
-
UCSF Scientists Eliminate Deadly Brain Tumors in Mice with B-SYNC Therapy
Engineered B-SYNC CAR-T cells successfully wiped out diffuse midline glioma in mice, paving the way for human clinical trials as early as…
-
Medicare Denies $949 Multi-Cancer Blood Test, Leaving Seniors With Full Bill Until 2029
Despite FDA advisory support, CMS excludes Galleri from coverage, forcing patients to pay out-of-pocket while awaiting a 2029 policy shift.
-
FDA orders class-wide GLP-1 label update for rare eye disease risk
The FDA requires all GLP-1 drugs, including Ozempic and Mounjaro, to warn of potential NAION risk, a rare condition causing sudden vision…
-
Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores
An analysis of how trial designs focused on immune response metrics bypass FDA requirements, potentially delaying approvals for lifesaving cancer combinations.
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992